At the time of writing, Contineum Therapeutics Inc [CTNM] stock is trading at $11.74, down -0.84%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CTNM shares have gain 26.10% over the last week, with a monthly amount glided 1.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Contineum Therapeutics Inc [NASDAQ: CTNM] stock has seen the most recent analyst activity on January 08, 2026, when Morgan Stanley downgraded its rating to a Equal-Weight but kept the price target unchanged to $14 for it. Previously, Leerink Partners started tracking the stock with Outperform rating on November 13, 2025, and set its price target to $22. On September 25, 2025, Leerink Partners initiated with a Outperform rating and assigned a price target of $20 on the stock. William Blair started tracking the stock assigning a Outperform rating. Robert W. Baird initiated its recommendation with a Outperform and recommended $32 as its price target on October 22, 2024. Stifel started tracking with a Buy rating for this stock on April 30, 2024, and assigned it a price target of $29. In a note dated April 30, 2024, RBC Capital Mkts initiated an Outperform rating and provided a target price of $30 on this stock.
For the past year, the stock price of Contineum Therapeutics Inc fluctuated between $3.35 and $13.49. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Contineum Therapeutics Inc [NASDAQ: CTNM] shares were valued at $11.74 at the most recent close of the market. An investor can expect a potential return of 49.06% based on the average CTNM price forecast.
Analyzing the CTNM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.32 and Total Capital is 0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Contineum Therapeutics Inc [NASDAQ:CTNM] has a current ratio of 29.07. In addition, the Quick Ratio stands at 29.07 and the Cash Ratio stands at 6.7.
Transactions by insiders
Recent insider trading involved Lorrain Daniel S., Chief Scientific Officer, that happened on Jan 05 ’26 when 4170.0 shares were sold. Officer, DANIEL LORRAIN completed a deal on Jan 05 ’26 to buy 4170.0 shares. Meanwhile, CMO & Head of Development Watkins Tim sold 3611.0 shares on Dec 29 ’25.
